# Rituximab

## Mabthera inj 100mg/10mL

#### 藥委會臨採

| 藥品代碼       | IMAB1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:---------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Treatment of patients with relapsed or chemoresistant indolent B-cell non-Hodgkin's lymphoma. In combination with CHOP or other chemotherapy agents in the treatment of diffuse large B-cell lymphoma patients. In combination with CVP chemotherapy agents in the untreated advanced follicular B-cell non-Hodgkin's lymphoma. Treatment of patients with follicular lymphoma as maintenance treatment， after response to induction therapy. In combination with methotrexate for treatment of adults with active RA who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 用法用量       | Administration rate (adult)- Initial infusion: Start infusion at a rate of 50 mg/hour; if there is no infusion-related reaction， increase the rate by 50 mg/hour increments every 30 minutes， to a maximum rate of 400 mg/hour.- Subsequent infusions: If patient tolerated initial infusion， start at 100 mg/hour; if there is no infusion-related reaction， increase the rate by 100 mg/hour increments every 30 minutes， to a maximum rate of 400 mg/hour. [Low-grade or Follicular Non-Hodgkin’s Lymphoma (NHL)] 375 mg/m2 once weekly for 4 doses. Retreatment following disease progression: 375 mg/m2 once weekly for 4 doses. Maintenance therapy (in untreated patients with response to induction therapy): 375 mg/m2 every 2 months until relapse or for maximum duration of 2 years. Maintenance therapy (relapsed/refractory): 375 mg/m2 every 3 months until relapse or for maximum duration of 2 years. [Diffuse Large B-cell NHL] 375 mg/m2 on day 1 of each chemotherapy cycle for up to 8 doses in combination with CHOP chemotherapy (cyclophosphamide， doxorubicin， prednisone and vincristine) [Chronic Lymphocytic Leukaemia (CLL)] 375 mg/m2 on the day prior to chemotherapy in cycle 1， then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 in combination with chemotherapy. [Rheumatoid Arthritis (RA)] 500-1000 mg on days 1 and 15; subsequent courses may be administered every 24 weeks (or based on clinical evaluation)， but no sooner than every 16 weeks. Premedication with methylprednisolone 100 mg IV is recommended 30 minutes prior to each rituximab dose. |
| 肝功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 禁忌           | Hypersensitivity to rituximab or murine proteins. Pregnancy， lactation. Active hepatits B disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 副作用         | Fever， chills or rigor， flushing， angioedema， nausea， urticaria/rash， fatigue， headache， pruritus， dyspnea， throat irritation， rhinitis， vomiting. Cardiovascular: Hypertension (all grades， 6%; grades 3 and 4， 1% )， Hypotension (all grades， 10%; grades 3 and 4， 1% ) Dermatologic: Pruritus Gastrointestinal: Abdominal pain (14% )， Diarrhea (10% )， Nausea (23% )， Vomiting (10% ) Neurologic: Asthenia (non-Hodgkin's lymphoma， all grades， 26%; grades 3 and 4， 1%; rheumatoid arthritis， 2% )， Dizziness (all grades， 10%; grades 3 and 4， 1% )， Headache (all grades， 19%; grades 3 and 4， 1% )， Sensory neuropathy (30% ) Other: Fever (all grades， 53%; grades 3 and 4， 1% )， Shivering (all grades， 33%; grades 3 and 4， 3% )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 孕期用藥建議   | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 哺乳期用藥建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## MABTHERA infusion 500mg/50mL

#### 常備臨採(不刪)

| 藥品代碼       | IMAB5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:---------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Treatment of patients with relapsed or chemoresistant indolent B-cell non-Hodgkin's lymphoma. In combination with CHOP or other chemotherapy agents in the treatment of diffuse large B-cell lymphoma patients. In combination with CVP chemotherapy agents in the untreated advanced follicular B-cell non-Hodgkin's lymphoma. Treatment of patients with follicular lymphoma as maintenance treatment， after response to induction therapy. In combination with methotrexate for treatment of adults with active RA who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 用法用量       | Administration rate (adult)- Initial infusion: Start infusion at a rate of 50 mg/hour; if there is no infusion-related reaction， increase the rate by 50 mg/hour increments every 30 minutes， to a maximum rate of 400 mg/hour.- Subsequent infusions: If patient tolerated initial infusion， start at 100 mg/hour; if there is no infusion-related reaction， increase the rate by 100 mg/hour increments every 30 minutes， to a maximum rate of 400 mg/hour. [Low-grade or Follicular Non-Hodgkin’s Lymphoma (NHL)] 375 mg/m2 once weekly for 4 doses. Retreatment following disease progression: 375 mg/m2 once weekly for 4 doses. Maintenance therapy (in untreated patients with response to induction therapy): 375 mg/m2 every 2 months until relapse or for maximum duration of 2 years. Maintenance therapy (relapsed/refractory): 375 mg/m2 every 3 months until relapse or for maximum duration of 2 years. [Diffuse Large B-cell NHL] 375 mg/m2 on day 1 of each chemotherapy cycle for up to 8 doses in combination with CHOP chemotherapy (cyclophosphamide， doxorubicin， prednisone and vincristine) [Chronic Lymphocytic Leukaemia (CLL)] 375 mg/m2 on the day prior to chemotherapy in cycle 1， then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 in combination with chemotherapy. [Rheumatoid Arthritis (RA)] 500-1000 mg on days 1 and 15; subsequent courses may be administered every 24 weeks (or based on clinical evaluation)， but no sooner than every 16 weeks. Premedication with methylprednisolone 100 mg IV is recommended 30 minutes prior to each rituximab dose. |
| 肝功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 禁忌           | Hypersensitivity to rituximab or murine proteins. Pregnancy， lactation. Active hepatits B disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 副作用         | Fever， chills or rigor， flushing， angioedema， nausea， urticaria/rash， fatigue， headache， pruritus， dyspnea， throat irritation， rhinitis， vomiting. Cardiovascular: Hypertension (all grades， 6%; grades 3 and 4， 1% )， Hypotension (all grades， 10%; grades 3 and 4， 1% ) Dermatologic: Pruritus Gastrointestinal: Abdominal pain (14% )， Diarrhea (10% )， Nausea (23% )， Vomiting (10% ) Neurologic: Asthenia (non-Hodgkin's lymphoma， all grades， 26%; grades 3 and 4， 1%; rheumatoid arthritis， 2% )， Dizziness (all grades， 10%; grades 3 and 4， 1% )， Headache (all grades， 19%; grades 3 and 4， 1% )， Sensory neuropathy (30% ) Other: Fever (all grades， 53%; grades 3 and 4， 1% )， Shivering (all grades， 33%; grades 3 and 4， 3% )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 孕期用藥建議   | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 哺乳期用藥建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

